NCT03325075View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Chikungunya Virus
Interventions
BIOLOGICAL

VAL-181388

Escalating dose levels

OTHER

Placebo

Saline

Trial Locations (1)

20850

Optimal Research, Rockville

All Listed Sponsors
collaborator

Defense Advanced Research Projects Agency

FED

lead

ModernaTX, Inc.

INDUSTRY

NCT03325075 - Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants | Biotech Hunter | Biotech Hunter